IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of ...
InMode Ltd. is rated a Strong Buy due to its robust balance sheet, proprietary technology, and international growth. Learn more about INMD stock here.
To the Board Members of InMode: InMode's valuation has continued to contract. We believe this is partly due to management's chaotic leadership; one reason sales remain low is the detrimental decision ...
InMode ended 2025 with $555.3 million in cash, cash equivalents, marketable securities and deposits, underscoring a strong balance sheet. The company returned $127.4 million to shareholders through ...
YOKNEAM, Israel, Feb. 2, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following statement ...
InMode INMD is preparing to release its quarterly earnings on Monday, 2025-04-28. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect InMode to ...
InMode Ltd. (NASDAQ:INMD) Q2 2025 Earnings Call Transcript July 30, 2025 InMode Ltd. beats earnings expectations. Reported EPS is $0.47, expectations were $0.43. Operator: Good day, and welcome to ...
Shares of InMode Ltd. (NASDAQ:INMD) gained about 2.5% in premarket trading on Monday after the company confirmed it is reviewing potential strategic alternatives. The medical technology firm said it ...
InMode expects full-year earnings in the range of $1.43 to $1.48 per share, with revenue in the range of $365 million to $375 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results